Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Capsuglutide
- Development stage
- Preclinical
- Lead developer
- Diabetology
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral
01
Overview
**Capsuglutide** is a preclinical oral fixed-dose combination being developed by Diabetology for type 2 diabetes mellitus. It combines Capsulin, an orally delivered insulin product intended to activate the insulin receptor, with Oraglutide, an oral glucagon-like peptide 1 receptor agonist. The capsule is designed to combine insulin-mediated glucose control with GLP-1 receptor agonism to improve glycaemic control through an oral peptide-delivery approach.
- Other names
- CapsuglutideCapsulin + Oraglutide
02
Targets
GLP1R (GLP-1R)INSR (Insulin receptor)
Beyond the preview
Go deeper on Capsuglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Capsuglutide.